How to treat histone 3 altered gliomas: molecular landscape and therapeutic developments.

Vincenzo Di Nunno Enrico FranceschiLidia GattoAlicia TosoniStefania BartoliniAlba Ariela Brandes

Published in: Expert review of clinical pharmacology (2022)

Thanks to an increased knowledge of the genomic landscape of these rare tumors, there are novels promising therapeutic targets for these malignancies. However, the majority of available trials allowed enrollment only in DMG, while few studies are focused on or allow the inclusion of DHG patients.

Keyphrases

end stage renal disease
newly diagnosed
chronic kidney disease
healthcare
peritoneal dialysis
prognostic factors
health insurance
patient reported outcomes
copy number
genome wide
single molecule